SP-96

SP-96 is a highly potent, selective and non-ATP-competitive Aurora B (IC50=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI50=107 nM) . SP-96 can be used for the research of triple negative breast cancer (TNBC) [1].

Product Specifications

CAS Number

[2682114-54-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Aurora Kinase

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/sp-96.html

Purity

99.65

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC(NC2=C3C=CC(C4=CN(C)N=C4)=CC3=NC=N2)=C1)NC5=CC=CC(F)=C5

Molecular Formula

C25H20FN7O

Molecular Weight

453.47

Precautions

H302, H315, H320, H335

References & Citations

[1]Naga Rajiv Lakkaniga, et al. Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression.Eur J Med Chem. 2020 Jul 12;203:112589.